Eli Lilly and Company

Novo Nordisk A/S

Dr. Reddy's Laboratories Limited

Sandoz Group AG

Hims & Hers Health, Inc.

The United Laboratories International Holdings Limited

Huadong Medicine Co., Ltd

DexCom, Inc.

Abbott Laboratories

Lupin Limited

The market for weight loss drugs that <a href="https://oninvest.com/article/vse-o-nikh-govoriat-kak-novye-preparaty-izmeniat-nashu-zhizn">revolutionized</a> pharmacoculture in the early 2020s is entering a new phase. This year, Novo Nordisk's patents for semaglutide, the active ingredient in Ozempic, perhaps the most famous drug in this class, will expire in five major countries. This means that generic manufacturers will enter the race, new numerous players who are already preparing to make money by flooding the world with inexpensive analogs.

Substance-for-money exchange: $32 billion semaglutide market enters patent collapse phase

Apple Inc.

Garmin Ltd.

Christian Dior SE

Population aging, which the WHO has repeatedly warned about, <a href="https://reports.weforum.org/docs/WEF_Future_Proofing_the_Longevity_Economy_2025.pdf">does</a> not only lead</a> to problems for public pension systems and <a href="https://oninvest.com/article/sidelka-i-medsestra-kak-ii-i-roboty-pomogaut-razresit-krizis-zaboty-o-pozilyh?ysclid=mbt7xrbc9n566151935">a care crisis</a>. There is money to be made from it.&nbsp;

The $8 trillion market: who's going to capitalize on longevity